US EditionPublished • loading... • Updated
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono gains exclusive worldwide rights to develop neurologic and immunologic small molecule drugs using Congruence’s Revenir platform, expanding beyond oncology since 2024.
Summary by WBOC 16
8 Articles
8 Articles
The Norfolk Daily News+4 Reposted by 4 other sources
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation
PR NewswireReposted by 
THE TIMES OF BENGAL
THE TIMES OF BENGALCongruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
/PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Congruence Therapeutics today announced...
·United States
Read Full Article
Ono Pharma Announces New Drug Discovery Collaboration with ...
·Crystal River, United States
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
